Further providing for pharmacy technician and pharmacy technician trainee registration, qualifications and supervision; providing for administration of injectable medications, biologicals and immunizations, for clinical laboratory certificate and for report on pharmacy-administered vaccines; and making a repeal.
HB1881 amends Pennsylvania’s Pharmacy Act to expand and clarify the scope of pharmacy practice around immunizations, injectable medications, and point-of-care testing. It updates pharmacy technician registration rules, including a grandfathering-style provision for certain technicians who practiced between January 29, 2019, and June 28, 2025, and who apply within a year after final regulations are issued. The bill also authorizes pharmacists, subject to board regulations and training requirements, to administer injectable medications, biologicals, and immunizations to patients age 8 and older, and influenza and COVID-19 immunizations by injectable or needle-free methods to patients age 5 and older.
The bill sets detailed conditions for pharmacist administration, including approved education and practical training, CPR certification, physician-established treatment guidelines, parental consent for minors, liability insurance, notification to a patient’s primary care provider, and continuing education requirements. It also allows limited delegation to pharmacy interns and, in some cases, to certain nurses or pharmacy technicians for influenza and COVID-19 immunizations under direct supervision. In addition, HB1881 creates authority for pharmacies with a federal waiver certificate to perform certain FDA-authorized tests for COVID-19, influenza, RSV, and strep, and it requires the Department of Health to report on pharmacy-administered vaccines and related child wellness impacts over time.
The bill’s impact on state law is to broaden the operational role of pharmacists and pharmacy staff in immunization delivery and limited diagnostic testing while tying that authority to regulatory standards from the State Board of Pharmacy and the Department of Health. It also repeals and replaces provisions of the Pharmacy Audit Integrity and Transparency Act to continue the legal framework for these services under new sections of the Pharmacy Act. Affected parties include pharmacists, pharmacy interns, pharmacy technicians, pharmacies with CLIA waiver certificates, the Department of Health, the State Board of Pharmacy, and patients receiving vaccines or tests, especially children and adolescents.
Overall sentiment appears generally favorable toward expanding pharmacy-based access to vaccines and testing, as reflected by the bill’s strong House floor passage and earlier committee approval. At the same time, the votes show meaningful opposition, suggesting some concern about shifting clinical responsibilities into pharmacies. The bill’s structure indicates an attempt to balance access with safeguards, which likely helped it gain broad support despite not being unanimous.
The main points of contention are likely to be patient safety, scope of practice, and oversight. Critics may question whether pharmacy technicians should administer vaccines, whether pharmacists should be able to provide these services to younger children, and whether the Department of Health should have broad authority to add or exclude immunizations based on medical evidence and public health determinations. Supporters are likely focused on convenience, access, and public health benefits, especially for routine immunizations and rapid testing.
HB1881 amends the Pharmacy Act to expand pharmacists’ authority to administer injectable medications, biologicals, and immunizations, and to authorize certain pharmacy-based laboratory tests for COVID-19, influenza, RSV, and strep when a pharmacy has the required federal waiver. It also revises pharmacy technician registration rules, creates reporting obligations for the Department of Health, and repeals and reenacts related provisions from the Pharmacy Audit Integrity and Transparency Act so the new framework continues existing authority under updated statutory sections.
The bill appears to have broad but not unanimous support. It passed the House with large margins at one stage and a narrower final-passage vote later, indicating that many lawmakers support expanding pharmacy access to vaccines and testing, while a substantial minority remains opposed or cautious. The overall tone suggests a policy consensus in favor of access and convenience, tempered by concerns about professional oversight and the safety of expanding pharmacy practice.
The most notable disagreements center on scope of practice and clinical oversight. Opponents are likely concerned about allowing pharmacists and, in limited cases, pharmacy technicians to administer vaccines to minors and perform testing, as well as the Department of Health’s authority to determine which immunizations may be added or excluded. Supporters emphasize public health access, especially for childhood immunizations, influenza and COVID-19 vaccination, and rapid point-of-care testing in pharmacies. The bill tries to address these concerns through training, supervision, insurance, parental consent, and reporting requirements.